ClinConnect ClinConnect Logo
Search / Trial NCT05905003

AMP SCZ® Observational Study: PREDICT-DPACC

Launched by BRIGHAM AND WOMEN'S HOSPITAL · Jun 6, 2023

Trial Information

Current as of July 21, 2025

Unknown status

Keywords

Biomarkers Phenotype

ClinConnect Summary

The AMP SCZ Observational Study, known as PREDICT-DPACC, is focused on understanding young people who are at a higher risk of developing serious mental health issues, particularly psychosis. The goal of this study is to create tools that can help predict whether these individuals will improve, experience a psychotic episode, or have ongoing symptoms that affect their daily lives. By gathering information from a large group of participants aged 12 to 30, the researchers aim to identify patterns that may help in providing better treatments for those at risk.

To participate, individuals must be between 12 and 30 years old and meet specific criteria indicating they are at clinical high risk for psychosis. Participants will undergo various assessments over 18 to 24 months, allowing researchers to track their symptoms and overall well-being. Importantly, those with a history of certain mental health conditions or who are currently taking specific medications may not be eligible. This study is currently recruiting participants from multiple countries, making it a significant international effort to improve understanding and treatment of high-risk mental health conditions.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Individuals between 12 and 30 years old;
  • Understand and sign an informed consent (or assent for minors) document;
  • Meet diagnostic criteria for CHR from the Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS (PSYCHS).
  • Exclusion Criteria:
  • Antipsychotic medication exposure equivalent to a total lifetime haloperidol dose of \>50 mg or current antipsychotic medication at time of screening assessment;
  • Documented history of intellectual disability;
  • Past or current clinically relevant central nervous system disorder;
  • Traumatic brain injury that is rated as 7 or above on the Traumatic Brain Injury screening instrument;
  • Current or past treated or untreated psychotic episode, as determined using the PSYCHS.
  • See also the AMP SCZ website link for a description of eligibility criteria (https://www.ampscz.org/participate/eligible/).

About Brigham And Women's Hospital

Brigham and Women's Hospital (BWH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As an integral part of the Partners HealthCare system, BWH combines cutting-edge medical education with a focus on patient-centered care, fostering an environment that promotes groundbreaking clinical trials across various specialties. The hospital is dedicated to translating scientific discoveries into effective treatments, making significant contributions to the fields of cardiovascular medicine, oncology, and women's health, among others. With a robust infrastructure for research and a collaborative approach, BWH aims to improve patient outcomes and enhance the overall quality of healthcare.

Locations

Pittsburgh, Pennsylvania, United States

Philadelphia, Pennsylvania, United States

Pittsburgh, Pennsylvania, United States

Pavia, , Italy

Boston, Massachusetts, United States

San Diego, California, United States

New Haven, Connecticut, United States

Saint Louis, Missouri, United States

Chapel Hill, North Carolina, United States

Chapel Hill, North Carolina, United States

Irvine, California, United States

New York, New York, United States

Calgary, Alberta, Canada

Philadelphia, Pennsylvania, United States

Athens, Georgia, United States

San Francisco, California, United States

San Francisco, California, United States

Evanston, Illinois, United States

London, , United Kingdom

Hartford, Connecticut, United States

Eugene, Oregon, United States

Queens, New York, United States

Los Angeles, California, United States

Adelaide, South Australia, Australia

Craigieburn, Victoria, Australia

Glenroy, Victoria, Australia

Melton South, Victoria, Australia

Parkville, Victoria, Australia

Sunshine, Victoria, Australia

Werribee, Victoria, Australia

Montréal, Quebec, Canada

Santiago, Región Metropolitana, Chile

Shanghai, , China

Copenhagen, , Denmark

Cologne, Brescia, Germany

Jena, Thuringia, Germany

Munich, , Germany

Hong Kong, , Hong Kong

Gwangju, , Korea, Republic Of

Seoul, , Korea, Republic Of

Singapore, , Singapore

Madrid, , Spain

Lausanne, , Switzerland

Birmingham, , United Kingdom

Cambridge, , United Kingdom

Santiago, , Chile

Patients applied

0 patients applied

Trial Officials

Martha E Shenton, Ph.D.

Principal Investigator

Brigham and Women's Hospital/Harvard Medical School

Scott Woods, M.D.

Principal Investigator

Yale University

Barnaby Nelson, Ph.D.

Principal Investigator

Center for Youth Mental Health at the University of Melbourne/Orygen

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported